TM9SF2

Across TCGA pan-cancer cohorts, TM9SF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM9SF2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TM9SF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TM9SF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where TM9SF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.464	0.867	.001	46	view →
LUAD	OS	Median	III,IV	0.738	0.238	.003	25	view →
CCRCC	OS	Median	All	0.647	1.000	.005	23	view →
PDAC	OS	Median	III,IV	0.923	0.589	.017	5	view →
HNSC	DFS	Quartile	III,IV	0.870	1.000	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TM9SF2–LSCC (DFS)

Open the LSCC breakdown →